Berta L. S.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase III Study of Rilvegostomig plus Combination Chemotherapy versus Durvalumab plus Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer
- Phase 3 Randomized Trial of Daraxonrasib Monotherapy or Daraxonrasib + Gemcitabine/Nab‑Paclitaxel vs Gemcitabine/Nab‑Paclitaxel in First‑Line Metastatic Pancreatic Cancer
- Phase 2 Evaluation of Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
Data & Insights
Has run more than one trial at 80 of 252 partner sites.
Specializations
Pancreatic Cancer Research
This investigator specializes in advanced treatments for pancreatic ductal adenocarcinoma, with particular focus on novel therapeutic combinations for metastatic disease.
- First-line treatment strategies
- Targeted therapies for CLDN18.2-positive tumors
- Advanced metastatic disease management
Their research encompasses innovative approaches including immunotherapy combinations and molecular-targeted agents.
Biliary Tract Oncology
The investigator conducts research in cholangiocarcinoma and related biliary tract malignancies, exploring novel therapeutic interventions.
- Advanced cholangiocarcinoma treatments
- Post-surgical therapeutic strategies
- Gallbladder cancer interventions
Their work includes evaluation of targeted therapies and post-resection treatment approaches.
Precision Medicine Applications
The investigator focuses on molecular-guided therapeutic approaches in gastrointestinal cancers.
- KRAS mutation-targeted therapies
- DNA damage repair pathways
- Biomarker-driven treatment selection
Their research emphasizes personalized treatment strategies based on specific genetic alterations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.